47m agoGuruFocusBEARISH 38Analyst
Why Is BIOVENTUS INC A (BVS) Stock Down Today?
By the Top Tier Newswire AI Desk · reviewed against 13 wire stories
BIOVENTUS INC A (BVS) is down -15.36% in the latest session. Our newswire has captured 13 stories on BVS across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for BVS publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
BVS by the numbers
Last: $11.13Session: -15.36%Coverage: 13 stories / 7 sourcesAI sentiment: 48/100 (mixed)
The headlines behind the move
51m agoThe FlyBEARISH 34Analyst
Bioventus price target lowered to $16 from $18 at Craig-Hallum
2h agoThe FlyBEARISH 34Analyst
Bioventus price target lowered to $16 from $18 at Barrington
3h agoThe FlyBEARISH 34Analyst
Bioventus price target lowered to $18 from $19 at Canaccord
7h agoGuruFocusNEUTRAL 54Earnings
Bioventus (BVS) Reports 3% Revenue Growth in Q3 2026 Amid Strategic Review
7h agoGuruFocusNEUTRAL 54Earnings
Bioventus Inc (BVS) Q3 2026 Earnings Call Highlights: Solid Pain and Ultrasonics Growth Offset by Bone Graft Softness
8h agoSeeking AlphaBULLISH 58Earnings
Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79
Bioventus Q3 2026 earnings: revenue guidance cut on BGS weakness, EPS reaffirmed, and Q4 acceleration expected.
8h agoSeeking AlphaNEUTRAL 50Earnings
Bioventus Inc. (BVS) Q3 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q3 2026 Earnings Call November 2, 2026 4:30 PM ESTCompany ParticipantsDavid Crawford - Vice President of Investor Relations &...
10h agoGuruFocusNEUTRAL 50Earnings
Q3 2026 Bioventus Inc. Earnings Call Transcript
11h agoThe Motley FoolBULLISH 58Earnings
Bioventus (BVS) Q3 2026 Earnings Call Transcript
Pain treatments drove 3% revenue growth as management targets $100M+ for nerve stimulation.
Frequently asked questions
Why is BVS stock down today?
BIOVENTUS INC A (BVS) is down -15.36% in the latest session. Our newswire has captured 13 stories on BVS across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100). The most recent driver: "BVS Maintained by Canaccord Genuity -- Price Target Lowered to $18.00" (GuruFocus).
Is BVS a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of BVS coverage reads 48/100 over 13 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is IBTA up today (+31.06%)
- Why is STVN down today (-26.19%)
- Why is AEHR up today (+25.75%)
- Why is IT down today (-17.78%)
- Why is BETA up today (+16.22%)
- Why is GPK up today (+15.70%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BVS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.